Harmony Biosciences (HRMY) Stock Forecast & Price Target

$30.76 -0.07 (-0.23%)

Closing price 04:00 PM Eastern

Extended Trading

$30.77 +0.01 (+0.03%)

As of 06:08 PM Eastern

Compare

Harmony Biosciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 11 Analyst Ratings

Sell
1

Hold
6

Buy
4

Based on 11 Wall Street analysts who have issued ratings for Harmony Biosciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 1 has given a sell rating, 6 have given a hold rating, and 4 have given a buy rating for HRMY.

Consensus Price Target

$40.89
32.93% Upside

According to the 11 analysts' twelve-month price targets for Harmony Biosciences, the average price target is $40.89. The highest price target for HRMY is $62.00, while the lowest price target for HRMY is $28.00. The average price target represents a forecasted upside of 32.93% from the current price of $30.76.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for HRMY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Harmony Biosciences and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HRMY Analyst Ratings Over Time

Type	Current Forecast 5/14/25 to 5/14/26	1 Month Ago 4/14/25 to 4/14/26	3 Months Ago 2/13/25 to 2/13/26	1 Year Ago 5/14/24 to 5/14/25
Strong Buy	0 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	6 Buy rating(s)	8 Buy rating(s)
Hold	6 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	2 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$40.89	$42.67	$45.63	$52.33
Forecasted Upside	32.93% Upside	45.67% Upside	26.70% Upside	56.73% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Buy

HRMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HRMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Harmony Biosciences Stock vs. The Competition

Type	Harmony Biosciences	Medical Companies	Broader Market
Consensus Rating Score	2.27	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	32.63% Upside	1,814.29% Upside	17.09% Upside
News Sentiment Rating	Positive News See Recent HRMY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/8/2026	Truist Financial 3 of 5 stars	Danielle Brill Not Rated	Boost Target	Hold	$25.00 ➝ $29.00	-7.95%
5/1/2026	Zacks Research Not Rated		Upgrade	Strong Sell ➝ Hold
4/29/2026	Weiss Ratings Not Rated		Downgrade	Hold (C) ➝ Hold (C-)
2/25/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	So Youn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$46.00 ➝ $36.00	+27.20%
2/25/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick R. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$55.00	+94.07%
2/25/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ami Fadia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$46.00 ➝ $44.00	+56.08%
2/25/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Gerberry Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Underperform	$32.00 ➝ $28.00	-0.67%
2/23/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Hoang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$31.00	+6.31%
2/19/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Graig Suvannavejh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$50.00	+41.94%
11/24/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andreas Argyrides Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$62.00	+80.71%
SpaceX eyes a 1.75 trillion valuation - here's what to know (Ad) Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500. See how to get positioned in SpaceX before the announcement goes public
7/10/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Corinne Johnson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral	$33.00	-4.78%
5/13/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Pete Stavropoulos Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
10/10/2024	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$40.00	+18.69%
6/21/2024	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	D. Hoang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$48.00	+66.61%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:11 PM ET.

HRMY Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Harmony Biosciences is $40.89, with a high forecast of $62.00 and a low forecast of $28.00.

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last twelve months. There is currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HRMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HRMY, but not buy additional shares or sell existing shares.

According to analysts, Harmony Biosciences's stock has a predicted upside of 32.93% based on their 12-month stock forecasts.

Over the previous 90 days, Harmony Biosciences's stock had 5 downgrades and 1 upgrade by analysts.

Harmony Biosciences has been rated by research analysts at Bank of America, Deutsche Bank Aktiengesellschaft, HC Wainwright, Mizuho, Needham & Company LLC, Truist Financial, UBS Group, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Harmony Biosciences less than other "medical" companies. The consensus rating score for Harmony Biosciences is 2.27 while the average consensus rating score for "medical" companies is 2.30. Learn more on how HRMY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Harmony Biosciences Recommendations

This page (NASDAQ:HRMY) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harmony Biosciences (HRMY) Stock Forecast & Price Target

Harmony Biosciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

HRMY Analyst Ratings Over Time

HRMY Analyst Recommendations By Month

HRMY Price Targets by Month

Harmony Biosciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

HRMY Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Harmony Biosciences Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harmony Biosciences (HRMY) Stock Forecast & Price Target

Harmony Biosciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

HRMY Analyst Ratings Over Time

HRMY Analyst Recommendations By Month

HRMY Price Targets by Month

Harmony Biosciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

HRMY Forecast - Frequently Asked Questions

What is Harmony Biosciences' forecast for 2026?

Should I buy or sell Harmony Biosciences stock right now?

Does Harmony Biosciences's stock price have much upside?

Has Harmony Biosciences been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Harmony Biosciences?

Do Wall Street analysts like Harmony Biosciences more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Harmony Biosciences Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools